These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32163353)

  • 1. Repurposing bioactive compounds for treating multidrug-resistant pathogens.
    Hummell NA; Kirienko NV
    J Med Microbiol; 2020 Jun; 69(6):881-894. PubMed ID: 32163353
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel Immune Modulators Enhance
    Hummell NA; Revtovich AV; Kirienko NV
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33408224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient and novel screening model for assessing the bioactivity of extracts against multidrug-resistant Pseudomonas aeruginosa using Caenorhabditis elegans.
    Zhou YM; Shao L; Li JA; Han LZ; Cai WJ; Zhu CB; Chen DJ
    Biosci Biotechnol Biochem; 2011; 75(9):1746-51. PubMed ID: 21897025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.
    Thangamani S; Younis W; Seleem MN
    PLoS One; 2015; 10(7):e0133877. PubMed ID: 26222252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen.
    Tharmalingam N; Rajmuthiah R; Kim W; Fuchs BB; Jeyamani E; Kelso MJ; Mylonakis E
    Microb Drug Resist; 2018 Jun; 24(5):666-674. PubMed ID: 29461939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections.
    Soo VW; Kwan BW; Quezada H; Castillo-Juárez I; Pérez-Eretza B; García-Contreras SJ; Martínez-Vázquez M; Wood TK; García-Contreras R
    Curr Top Med Chem; 2017; 17(10):1157-1176. PubMed ID: 27697046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-house chemical library repurposing: A case example for Pseudomonas aeruginosa antibiofilm activity and quorum sensing inhibition.
    Ravithej Singh L; Tripathi VC; Raj S; Kumar A; Gupta S; Horam S; Upadhyay A; Kushwaha P; Arockiaraj J; Sashidhara KV; Pasupuleti M
    Drug Dev Res; 2018 Dec; 79(8):383-390. PubMed ID: 30291767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections.
    Younis W; Thangamani S; Seleem MN
    Curr Pharm Des; 2015; 21(28):4106-11. PubMed ID: 25961308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model.
    Sánchez-Diener I; Zamorano L; López-Causapé C; Cabot G; Mulet X; Peña C; Del Campo R; Cantón R; Doménech-Sánchez A; Martínez-Martínez L; Arcos SC; Navas A; Oliver A
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics.
    Konreddy AK; Rani GU; Lee K; Choi Y
    Curr Med Chem; 2019; 26(28):5363-5388. PubMed ID: 29984648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic and antibiofilm properties of ocellatin peptides against multidrug-resistant Pseudomonas aeruginosa.
    Bessa LJ; Eaton P; Dematei A; Plácido A; Vale N; Gomes P; Delerue-Matos C; Sa Leite JR; Gameiro P
    Future Microbiol; 2018 Feb; 13():151-163. PubMed ID: 29308671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options.
    M Campos JC; Antunes LC; Ferreira RB
    Future Microbiol; 2020 May; 15():649-677. PubMed ID: 32495702
    [No Abstract]   [Full Text] [Related]  

  • 13. Swietenia macrophylla extract promotes the ability of Caenorhabditis elegans to survive Pseudomonas aeruginosa infection.
    Dharmalingam K; Tan BK; Mahmud MZ; Sedek SA; Majid MI; Kuah MK; Sulaiman SF; Ooi KL; Khan NA; Muhammad TS; Tan MW; Shu-Chien AC
    J Ethnopharmacol; 2012 Jan; 139(2):657-63. PubMed ID: 22193176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of chitosan-alginate microspheres with high antimicrobial and antibiofilm activity against multi-drug resistant microbial pathogens.
    Thaya R; Vaseeharan B; Sivakamavalli J; Iswarya A; Govindarajan M; Alharbi NS; Kadaikunnan S; Al-Anbr MN; Khaled JM; Benelli G
    Microb Pathog; 2018 Jan; 114():17-24. PubMed ID: 29138082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of novel chalcones and modulation of virulence factors in hospital strains of Acinetobacter baumannii and Pseudomonas aeruginosa.
    Ušjak D; Ivković B; Božić DD; Bošković L; Milenković M
    Microb Pathog; 2019 Jun; 131():186-196. PubMed ID: 30980878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate.
    Mohamed MF; Brezden A; Mohammad H; Chmielewski J; Seleem MN
    Biochim Biophys Acta Gen Subj; 2017 Apr; 1861(4):848-859. PubMed ID: 28132897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms.
    Chromy BA; Elsheikh M; Christensen TL; Livingston D; Petersen K; Bearinger JP; Hoeprich PD
    Future Microbiol; 2012 Aug; 7(8):1011-20. PubMed ID: 22913359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.
    Pollini S; Brunetti J; Sennati S; Rossolini GM; Bracci L; Pini A; Falciani C
    J Pept Sci; 2017 Apr; 23(4):329-333. PubMed ID: 28176481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant
    Cheng YS; Sun W; Xu M; Shen M; Khraiwesh M; Sciotti RJ; Zheng W
    Front Cell Infect Microbiol; 2018; 8():438. PubMed ID: 30662875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.